Sponsored Links
| RegeneRx Receives Australian Patent For Treating Eye Disorders With Tβ4 |
 |
 |
 |
| Medical News - Eye Health | |||
|
Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the "Company" or "RegeneRx") announced today that it received a patent for treating disorders of the eye with Tβ4, including treatment for corneal vacuolization (cell debris), corneal stromal edema (tissue swelling), and healing associated with eye surgery including LASIK and PRK. The patent was issued in Australia, covers Tβ4, its analogues, isoforms and other derivatives and expires in 2022. Read more: Eye Health / Blindness News From Medical News Today
|